Net Income
Net Income
Regeneron Pharmaceuticals Net Income decreased by 13.9% to $727.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 10.1%, from $808.70M to $727.20M. Over 4 years (FY 2021 to FY 2025), Net Income shows a downward trend with a -13.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionNet Income
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Higher values indicate greater profitability and financial health, directly impacting shareholder value.
Detailed definition
The final bottom-line profit of the company after all operating expenses, non-operating expenses, and income taxes have...
Peer comparison
The most common metric for evaluating company performance against industry competitors.
Metric ID:
net_incomeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.10B | $1.63B | $2.23B | $973.50M | $852.10M | $1.32B | $1.20B | $817.80M | $968.40M | $1.01B | $1.16B | $722.00M | $1.43B | $1.34B | $917.70M | $808.70M | $1.39B | $1.46B | $844.60M | $727.20M |
| QoQ Change | — | -47.3% | +36.6% | -56.3% | -12.5% | +54.4% | -9.0% | -31.7% | +18.4% | +4.1% | +15.1% | -37.7% | +98.4% | -6.4% | -31.5% | -11.9% | +72.1% | +4.9% | -42.2% | -13.9% |
| YoY Change | — | — | — | — | -72.5% | -19.4% | -46.3% | -16.0% | +13.6% | -23.4% | -3.1% | -11.7% | +47.9% | +33.0% | -20.9% | +12.0% | -2.8% | +8.9% | -8.0% | -10.1% |
Range$722.00M – $3.10B
CAGR-26.3%
Avg YoY Growth-7.4%
Median YoY Growth-9.0%
Current Streak2 quarters decline
Net Income at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's net income?
- Regeneron Pharmaceuticals (REGN) reported net income of $727.20M in Q1 2026.
- How has Regeneron Pharmaceuticals's net income changed year-over-year?
- Regeneron Pharmaceuticals's net income decreased by 10.1% year-over-year, from $808.70M to $727.20M.
- What is the long-term trend for Regeneron Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's net income has grown at a -13.6% compound annual growth rate (CAGR), from $8.08B to $4.50B.
- What does net income mean?
- The total profit remaining after all costs, expenses, and taxes have been paid.